This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Fundamentals Impressive Amid Tough Competition
by Zacks Equity Research
Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.
S&P 500 Nears 2,500: 5 Stock Picks for Big Profits
by Swarup Gupta
The index has nearly always gained in the one-year period immediately following this winning streak.
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, China Life Insurance, Deere and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, China Life Insurance, Deere and American Airlines
8 Factors That Make Thermo Fisher a Valuable Pick Right Now
by Zacks Equity Research
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
Top Research Reports for Comcast, Thermo Fisher & China Life Insurance
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Thermo Fisher (TMO), and China Life Insurance (LFC).
Thermo Fisher Acquires Patheon, Boosts Laboratory Products
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.
Luminex Partners Sutter Health to Boost Molecular Testing
by Zacks Equity Research
The latest development is a significant addition to Luminex's (LMNX) molecular testing and diagnostic portfolio. The company has a broad product portfolio that comprises the advanced ARIES platform.
Thermo Fisher (TMO) Up 1.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.
Agilent (A) Sues Former Employees for Infringing IP Rights
by Zacks Equity Research
Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.
Thermo Fisher's Patheon Buyout Gains Antitrust Clearance
by Zacks Equity Research
Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.
Zimmer (ZBH) Tops Q2 Earnings, Drops View on Dull Sales
by Zacks Equity Research
Zimmer Biomet's (ZBH) Q2 earnings results disappoint with an unimpressive Knee, Hip and Dental performances.
Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up
by Zacks Equity Research
Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.
Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up
by Zacks Equity Research
Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.
Thermo Fisher (TMO) Beats on Q2 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high in Q2 banking on its analytical instruments segment in particular.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View
by Zacks Equity Research
Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
Medical Instruments' Jul 26 Earnings Lineup: EW, TMO, VAR
by Zacks Equity Research
The ongoing political conflict resulting in a delay in policy implementation is a major dampener for Q2 earnings in the Medical space.
Should You Buy Thermo Fisher Scientific Inc. (TMO) Ahead of Earnings?
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
What's in the Offing for Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.
Can Illumina (ILMN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.
What's in the Cards for DaVita (DVA) this Earnings Season?
by Zacks Equity Research
Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?
by Zacks Equity Research
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?
by Zacks Equity Research
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.